Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22332330 | 0.85 | GAA (0.41) | KMT2AMEN1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL20381502 | 0.83 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2POLBLMNA | |
| SCHEMBL20939096 | 0.82 | HSD17B10 (0.61) | KMT2AMEN1SMN1; SMN2GAALMNA | |
| SCHEMBL26140361 | 0.81 | HRH3 (0.40) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25959564 | 0.81 | TSHR (0.39) | KMT2AMEN1SMN1; SMN2GAALMNA | |
| SCHEMBL25771063 | 0.80 | KMT2A (0.51) | KMT2AMEN1SMN1; SMN2POLBGAA | |
| SCHEMBL23674877 | 0.80 | HPGD (0.61) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25039064 | 0.80 | ALDH1A1 (0.57) | KMT2AMEN1SMN1; SMN2POLBGAA | |
| SCHEMBL20381522 | 0.80 | HSD17B10 (0.44) | KMT2AMEN1SMN1; SMN2GAALMNA | |
| SCHEMBL20939164 | 0.78 | POLB (0.39) | KMT2AMEN1SMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | KMT2A 1832/4885MEN1 2804/4885SMN1; SMN2 3432/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | KMT2A 1832/4885MEN1 2804/4885SMN1; SMN2 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.